Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
The Akkermansia Company operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio shows 1 pending office action. This action is distributed across 1 distinct examiner and 1 distinct art unit, indicating a highly concentrated prosecution focus at this stage of the company's intellectual property development.
The busiest examiner for this portfolio is MOREAU, NASHARA LOUISE, who is responsible for 1 pending office action. Because this is the total pending workload, MOREAU, NASHARA LOUISE handles all current pending matters. This concentration in 1 distinct art unit and with 1 distinct examiner suggests a narrow technological or legal front for the company's current patent activities. Practitioners should note that the outcome of this specific office action will significantly impact the overall status of the company's pending biotechnology assets. Managing a relationship with this examiner in this art unit allows for a highly focused prosecution strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOREAU, NASHARA LOUISE | 1 | 80.0% | -100.0% |
| DEVI, SARVAMANGALA | 1 | 65.3% | +55.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18684682 | COMPOSITION COMPRISING PASTEURIZED AKKERMANSIA FOR THE TREATMENT OR PREVENTION OF IBS-RELATED ANXIETY | MOREAU, NASHARA LOUISE | 8d overdue |
| 18035766 | COMPOSITION COMPRISING AKKERMANSIA MUCINIPHILA AND GREEN TEA EXTRACT | DEVI, SARVAMANGALA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18035766 | COMPOSITION COMPRISING AKKERMANSIA MUCINIPHILA AND GREEN TEA EXTRACT | DEVI, SARVAMANGALA | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| 1645 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18684682 | COMPOSITION COMPRISING PASTEURIZED AKKERMANSIA FOR THE TREATMENT OR PREVENTION OF IBS-RELATED ANXIETY | MOREAU, NASHARA LOUISE | 1655 | §101§102§103§112 | Non-Final OA | 8d overdue | Pending | Feb 18, 2024 |
| 18035766 | COMPOSITION COMPRISING AKKERMANSIA MUCINIPHILA AND GREEN TEA EXTRACT | DEVI, SARVAMANGALA | 1645 | §103§112 | Final Rejection | — | Pending | May 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial